Interobserver Reliability of the 5-Point Deauville Score and SUV-Based Quantification of FDG PET/CT Scans in High-Risk Pediatric Hodgkin Lymphoma
Authors:
- Lindsay RenfroLRLindsay Renfro
- Steve Y. ChoSCSteve Y. Cho
Open Access
- 30 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 1 (2)
Abstract
Purpose: In lymphomas, the Deauville score (DS) standardizes 18F-FDG PET treatment response assessments. We assessed interobserver agreement of the DS and developed a quantitative PET-based parameter to minimize subjectivity of response assessments. Methods: PET scans performed within the Children’s Oncology Group AHOD0831 study were analyzed. One hundred one scans obtained after the first cycle of chemotherapy (PET1) and 83 obtained after the second cycle (PET2) were eligible for inclusion. Each scan was assigned a DS by 2 nuclear medicine radiologists and a Hodgkin lymphoma index (HLI), defined as the ratio of the tumor’s SUVmax or SUVpeak to the liver’s SUVmean. Cohen κ coefficient measured the rate of agreement of the DS assigned by the 2 radiologists. Receiver operating characteristic curves and the Youden index were used with the consensus DS to identify an optimal HLI cutoff value to distinguish PET-negative from PET-positive images. For each HLI cutoff value, sensitivity, specificity, and accuracy were calculated. Results: Interobserver agreement in DS was moderate (PET1: κ = 0.480, P < 0.001; PET2: κ = 0.428, P < 0.001). On PET1, the optimal cutoff values for HLImax were 1.19 for DS2/DS3 and 1.78 for DS3/DS4, and for HLIpeak were 1.19 for DS2/DS3 and 1.44 for DS3/DS4. On PET2 images, the corresponding values were 1.18, 1.58, 0.94, and 1.26. The most accurate predictor was HLImax on PET2 when scans were dichotomized as DS1–DS3 versus DS4–DS5 (accuracy, 92.8%; sensitivity, 100%; specificity, 91.8%). Conclusion: The HLI provides an objective, quantitative measure of disease response and thus may improve interreader agreement for lymphoma response assessments.Keywords
This publication has 21 references indexed in Scilit:
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration studyThe Lancet Oncology, 2023
- Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s LymphomaNew England Journal of Medicine, 2022
- Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trialThe Lancet Oncology, 2022
- Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)Annals of Nuclear Medicine, 2016
- Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmaxEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009